Amy D DiVasta1, Henry A Feldman2, Jennifer M O'Donnell3, Jin Long4, Mary B Leonard4, Catherine M Gordon5. 1. Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Division of Gynecology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: amy.divasta@childrens.harvard.edu. 2. Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts; Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts. 3. Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey. 4. Division of Pediatric Nephrology, Stanford University School of Medicine, Palo Alto, California. 5. Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts; Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts.
Abstract
PURPOSE:Adolescents with anorexia nervosa (AN) have decreased dehydroepiandrosterone (DHEA) and estrogen concentrations that may contribute to skeletal deficits. We sought to determine whether DHEA + estrogen replacement (ERT) prevented bone loss in young adolescents with AN. METHODS:We recruited females with AN (n = 70, ages 11-18 years) into a 12-month, randomized, double-blind placebo-controlled trial. Participants were randomized to oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/.1 mg levonorgestrel daily (n = 35) or placebo (n = 35). Outcomes included serial measures of bone mineral density (BMD) by dual-energy X-ray absorptiometry (total body, hip, spine) and peripheral quantitative computed tomography (pQCT; tibia). Magnetic resonance imaging of T1-weighted images of the left knee determined physeal status (open/closed). RESULTS:Sixty-two subjects completed the trial. Physeal closure status was the strongest predictor of aBMD changes. Among girls with open physes, those who received DHEA + ERT showed a decline in BMD Z-scores compared with those receiving placebo, whereas there was no effect in those with at least one closed physis. Treatment did not affect any pQCT measures, regardless of physeal closure status. CONCLUSIONS:Combined DHEA + ERT did not significantly improve dual-energy X-ray absorptiometry or pQCT BMD measurements in young adolescent girls with AN, in contrast to an earlier trial showing benefit in older adolescents and young women. In girls with open physes, the mean change in the placebo arm was greater than that of the DHEA + ERT group. We conclude that DHEA + ERT is ineffective for preserving bone health in growing young adolescents with AN at the dose and route of administration described in this report.
RCT Entities:
PURPOSE: Adolescents with anorexia nervosa (AN) have decreased dehydroepiandrosterone (DHEA) and estrogen concentrations that may contribute to skeletal deficits. We sought to determine whether DHEA + estrogen replacement (ERT) prevented bone loss in young adolescents with AN. METHODS: We recruited females with AN (n = 70, ages 11-18 years) into a 12-month, randomized, double-blind placebo-controlled trial. Participants were randomized to oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/.1 mg levonorgestrel daily (n = 35) or placebo (n = 35). Outcomes included serial measures of bone mineral density (BMD) by dual-energy X-ray absorptiometry (total body, hip, spine) and peripheral quantitative computed tomography (pQCT; tibia). Magnetic resonance imaging of T1-weighted images of the left knee determined physeal status (open/closed). RESULTS: Sixty-two subjects completed the trial. Physeal closure status was the strongest predictor of aBMD changes. Among girls with open physes, those who received DHEA + ERT showed a decline in BMD Z-scores compared with those receiving placebo, whereas there was no effect in those with at least one closed physis. Treatment did not affect any pQCT measures, regardless of physeal closure status. CONCLUSIONS: Combined DHEA + ERT did not significantly improve dual-energy X-ray absorptiometry or pQCT BMD measurements in young adolescent girls with AN, in contrast to an earlier trial showing benefit in older adolescents and young women. In girls with open physes, the mean change in the placebo arm was greater than that of the DHEA + ERT group. We conclude that DHEA + ERT is ineffective for preserving bone health in growing young adolescents with AN at the dose and route of administration described in this report.
Authors: Sogol Mostoufi-Moab; Jeremy Magland; Elizabeth J Isaacoff; Wenli Sun; Chamith S Rajapakse; Babette Zemel; Felix Wehrli; Karuna Shekdar; Joshua Baker; Jin Long; Mary B Leonard Journal: J Bone Miner Res Date: 2015-05-10 Impact factor: 6.741
Authors: Neville H Golden; Leora Lanzkowsky; Janet Schebendach; Christopher J Palestro; Marc S Jacobson; I Ronald Shenker Journal: J Pediatr Adolesc Gynecol Date: 2002-06 Impact factor: 1.814
Authors: G Theintz; B Buchs; R Rizzoli; D Slosman; H Clavien; P C Sizonenko; J P Bonjour Journal: J Clin Endocrinol Metab Date: 1992-10 Impact factor: 5.958
Authors: Leslie A Soyka; Madhusmita Misra; Aparna Frenchman; Karen K Miller; Steven Grinspoon; David A Schoenfeld; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2002-09 Impact factor: 5.958
Authors: Kirsten Ecklund; Sridhar Vajapeyam; Henry A Feldman; Catherine D Buzney; Robert V Mulkern; Paul K Kleinman; Clifford J Rosen; Catherine M Gordon Journal: J Bone Miner Res Date: 2010-02 Impact factor: 6.741
Authors: Vibha Singhal; Amita Bose; Meghan Slattery; Melanie S Haines; Mark A Goldstein; Nupur Gupta; Kathryn S Brigham; Seda Ebrahimi; Kristin N Javaras; Mary L Bouxsein; Kamryn T Eddy; Karen K Miller; David Schoenfeld; Anne Klibanski; Madhusmita Misra Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 5.958